2021-12-24
back
羅氏快篩_唯一台灣經WHO認證抗原快篩套組
在疫情四起的時刻，羅氏決不會坐以待斃，為了保證羅氏快篩的可信度，將羅氏快篩送至WHO世界衛生組織進行變種病毒認證，也得到羅氏快篩可偵測變異病毒的認可，在人人自危的狀況下，可信賴的羅氏快篩是您防疫的最佳守門員! 羅氏與康誠必為企業做到最好的防護。

No impact of the following virus variants has been observed on the Roche SARS- CoV-2 Rapid Antigen Testing Portfolio:
 
Country first reported in WHO
Nomenclature		 WHO
Classification
Lineage		 Country first reported in WHO
Nomenclature		 WHO
Classification
Lineage
UK Alpha VOC B.1.1.7 USA Epsilon VUM B.1.429
South Africa Beta VOC B.1.351 Iota VUM B.1.526
Japan/Brazil Gamma VOC P.1 B.1.526.2
India Delta VOC B.1.617.2 Egypt N/A C.36
Peru Lambda VOI C.37 Colombia Mu B.1.621
Colombia Mu VOI B.1.621 Brazil Zeta P.2
India Kappa
N/A
Delta Plus
Delta Plus
Delta Plus		 VUM B.1.617.1
B.1.617.3
AY.1
AY.2
AY.3		 Multiple countries Eta VUM B.1.525
  Phillipines Theta P.3
  UK A.23.1
  France B.1.616
USA Epsilon VUM B.1.427   Russia AT.1
VOC: Variant of Concern, VOI: Variant of Interest, VUM: Variant Under Monitoring

As emerging virus variants are identified, we commit to continuously monitor them independently and in collaboration with our partner, SD Biosensor.

References
  1. SD Biosensor, Analytical Study (in-silico testing): Q COVID-19 Ag_SARS-CoV-2 Variants in-silico analysis_Rev.03
  2. SD Biosensor, Analytical Study (wet testing): SARS-CoV-2 Variants LOD test as recombinant protein_Rev.06

Published by Roche Diagnostics International Ltd. | 6343 Rotkreuz, Switzerland | © 2021 | www.roche.com